Adamas Pharmaceuticals, Inc. clinical trials
Acquired by Supernus Pharmaceuticals, Inc., Nov 24, 2021 · source ↗
The registry lists 10 studies whose lead sponsor is Adamas Pharmaceuticals, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 16, 2022.
Before and after it joined Supernus Pharmaceuticals, Inc.
- First submitted before Adamas Pharmaceuticals, Inc. became part of Supernus Pharmaceuticals, Inc.
- 10
- First submitted after Adamas Pharmaceuticals, Inc. became part of Supernus Pharmaceuticals, Inc.
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Adamas Pharmaceuticals, Inc.10 studies
Something wrong with this grouping? Tell us on the Supernus Pharmaceuticals, Inc. page.
Studies
Recruiting first, then most recently updated. Showing 10 of 10. All Supernus Pharmaceuticals, Inc. studies →
- Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LIDTerminatedNCT02153632Phase 3
Sponsor listed in the registry: Adamas Pharmaceuticals, Inc. · First submitted before Adamas Pharmaceuticals, Inc. became part of Supernus Pharmaceuticals, Inc.
- Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.TerminatedNCT02153645Phase 3
Sponsor listed in the registry: Adamas Pharmaceuticals, Inc. · First submitted before Adamas Pharmaceuticals, Inc. became part of Supernus Pharmaceuticals, Inc.
- A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking ImpairmentCompletedNCT03567057Phase 3
Sponsor listed in the registry: Adamas Pharmaceuticals, Inc. · First submitted before Adamas Pharmaceuticals, Inc. became part of Supernus Pharmaceuticals, Inc.
- Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking ImpairmentCompletedNCT03436199Phase 3
Sponsor listed in the registry: Adamas Pharmaceuticals, Inc. · First submitted before Adamas Pharmaceuticals, Inc. became part of Supernus Pharmaceuticals, Inc.
- Open-Label Safety Study of ADS-5102 in PD Patients With LIDCompletedNCT02202551Phase 3
Sponsor listed in the registry: Adamas Pharmaceuticals, Inc. · First submitted before Adamas Pharmaceuticals, Inc. became part of Supernus Pharmaceuticals, Inc.
- ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)CompletedNCT02136914Phase 3
Sponsor listed in the registry: Adamas Pharmaceuticals, Inc. · First submitted before Adamas Pharmaceuticals, Inc. became part of Supernus Pharmaceuticals, Inc.
- Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced DyskinesiaCompletedNCT02274766Phase 3
Sponsor listed in the registry: Adamas Pharmaceuticals, Inc. · First submitted before Adamas Pharmaceuticals, Inc. became part of Supernus Pharmaceuticals, Inc.
- Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)CompletedNCT01397422Phase 2/3
Sponsor listed in the registry: Adamas Pharmaceuticals, Inc. · First submitted before Adamas Pharmaceuticals, Inc. became part of Supernus Pharmaceuticals, Inc.
- Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking ImpairmentCompletedNCT02471222Phase 2
Sponsor listed in the registry: Adamas Pharmaceuticals, Inc. · First submitted before Adamas Pharmaceuticals, Inc. became part of Supernus Pharmaceuticals, Inc.
- Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised SubjectsCompletedNCT00979251Phase 2
Sponsor listed in the registry: Adamas Pharmaceuticals, Inc. · First submitted before Adamas Pharmaceuticals, Inc. became part of Supernus Pharmaceuticals, Inc.